Molecular and metabolic differences of treatment responders versus nonresponders in a phase 0 clinical trial of metformin in endometrial cancer

Authors :: Paola A. Gehrig
Dario R. Roque
Kevin Schuler
Victoria L. Bae-Jump
Siobhan O'Connor
Liza Makowski
Brante P. Sampey
Dhiren R. Thakker
Ruth S. Everett
Brooke S. Rambally
Source :: Gynecologic Oncology. 141:20
Publication Year :: 2016
Publisher :: Elsevier BV, 2016.
Abstract: e22259 Background: In a phase 0 clinical trial of metformin in endometrial cancer (EC) patients, we previously reported that metformin decreased proliferation in the tumors of the majority of patie...

Subjects :: Gynecology
Oncology
Cancer Research
medicine.medical_specialty
endocrine system diseases
business.industry
Endometrial cancer
digestive, oral, and skin physiology
nutritional and metabolic diseases
Obstetrics and Gynecology
medicine.disease
Metformin
Clinical trial
Non responders
Internal medicine
Medicine
business
medicine.drug

Full Text Access

Tools